Last update 28 Jun 2025

HR-003

Overview

Basic Info

Drug Type
CAR-T
Synonyms
Anti BCMA CAR T cell therapy (Hrain Biotechnology), BCMA-CART, Human BCMA Targeted T Cells (Hrain Biotechnology)
+ [2]
Target
BCMA
Action
modulators
Mechanism
BCMA modulators(B-cell maturation protein modulators), T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Multiple MyelomaRelapse multiple myeloma
Inactive Indication
BCMA Positive Multiple MyelomaRefractory Multiple Myeloma
Originator Organization
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
Active Organization
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationBreakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Related

5
Clinical Trials associated with HR-003
NCT05594797
/ RecruitingPhase 2
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection Therapy for Relapsed/Refractory Multiple Myeloma
NCT05302648
/ Active, not recruitingEarly Phase 1
A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with Relapsed/Refractory Multiple Myeloma
NCT03943472
/ Unknown statusEarly Phase 1
A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With Relapsed/Refractory Multiple Myeloma
100 Clinical Results associated with HR-003
Login to view more data
100 Translational Medicine associated with HR-003
Login to view more data
100 Patents (Medical) associated with HR-003
Login to view more data
100 Deals associated with HR-003
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 2
China
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
12 Jul 2022
Refractory Multiple MyelomaPhase 1
China
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
08 Jul 2019
Relapse multiple myelomaPhase 1
China
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
08 Jul 2019
BCMA Positive Multiple MyelomaPhase 1
China
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.
15 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free